Evoke Pharma announces listing of new GIMOTI patent in FDA Orange Book

Evoke Pharma (EVOK) announced that U.S. Patent No. 12,377,064 covering the use of GIMOTI nasal spray in patients with moderate to severe symptoms of gastroparesis, has been listed in the U.S. Food and Drug Administration’s, FDA, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the “Orange Book”. “We believe the listed patent shows our commitment to developing innovative products that expand options for patients and providers, while also protecting our hard work and investment in innovation,” said Matt D’Onofrio, Chief Executive Officer of Evoke Pharma.